pn 401 has been researched along with Adenocarcinoma in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Saif, MW; von Borstel, R | 1 |
Abbruzzese, JL; Cobb, PW; Doroshow, JH; Issell, BF; Macdonald, JS; McCoy, S; Patel, T; Yost, KJ | 1 |
1 trial(s) available for pn 401 and Adenocarcinoma
Article | Year |
---|---|
Phase II trial of PN401, 5-FU, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach: a Southwest Oncology Group study.
Topics: Acetates; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Stomach Neoplasms; Survival Analysis; Uridine | 2006 |
1 other study(ies) available for pn 401 and Adenocarcinoma
Article | Year |
---|---|
5-Fluorouracil dose escalation enabled with PN401 (triacetyluridine): toxicity reduction and increased antitumor activity in mice.
Topics: Acetates; Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Maximum Tolerated Dose; Mice; Mice, Inbred BALB C; Survival Rate; Tumor Burden; Uridine; Xenograft Model Antitumor Assays | 2006 |